婴幼儿活体肝移植术中静脉注射顺阿曲库铵的药效学研究

doi:10.3969/j.issn.1674-8115.2021.06.009

摘要/Abstract

摘要：

目的·观察婴幼儿活体肝移植术中静脉注射顺阿曲库铵的药效学变化。方法·选择终末肝病期需择期行活体肝移植术的婴幼儿16例，年龄6~24个月，美国麻醉师协会（American Society of Anesthesiologists，ASA）分级为Ⅲ级或Ⅳ级。采用TOF-Watch肌松监测仪对尺神经进行连续4个成串刺激（train-of-four，TOF），观察拇内收肌的加速度变化。静脉注射0.15 mg/kg顺阿曲库铵诱导，T₁为最大抑制程度时，行气管插管。T₁恢复至3%时，输注起始剂量为2 μg/（kg·min）的顺阿曲库铵，调节速率，维持90%~95%肌松抑制程度。分别记录注射首剂量顺阿曲库铵后药物的起效时间、TOF无反应期、术中不同分期肌松药的用量；观察停药后患者的肌松恢复情况，包括停药后T₁从10%恢复至25%时间、恢复指数（T₁从25%恢复至75%的时间）以及4个成串刺激比值（TOFr）=0.9的时间。结果·肝移植术中顺阿曲库铵的平均输注速率为（1.37±0.46） μg/（kg·min）；术中无肝前期、无肝期以及新肝期的药物平均输注速率呈现下降趋势，但差异无统计学意义（P=0.110）。顺阿曲库铵的起效时间为（242.63±46.74）s，TOF无反应期为（34.02±7.71）min。停药后，T1恢复至25%时间为（12.80±3.49）min，恢复指数为（15.12±4.59）min，TOFr=0.9的时间为（40.27±7.03）min。结论·终末肝病患儿行活体肝移植术时，应充分认识肌松药的药效学特征；使用0.15 mg/kg的顺阿曲库铵麻醉诱导时，应在用药4 min后进行气管插管。在麻醉维持阶段，顺阿曲库铵的用药量在3个不同时期基本保持不变，1.4 μg/（kg·min）的药物输注速率能提供满意的肌松效果。

关键词: 肝移植, 婴幼儿, 顺阿曲库铵, 药效动力学

Abstract:

Objective·To observe pharmacodynamics of cisatracurium intravenously infused in infants and young children with end-stage liver disease during living donor liver transplantation.

Methods·Sixteen patients of American Society of Anesthesiologists (ASA) physical status Ⅲ and Ⅳ, aged 6－24 months, with end-stage liver disease, undergoing liver transplantation were studied. Neuromuscular transmission was monitored by the responses of the adductor pollicis to train-of-four (TOF) stimulation of ulnar nerve, using the accelerography (TOF-Watch). Endotracheal intubation was performed after intravenous injection of 0.15 mg/kg cisatracurium, with T₁ being the maximum inhibitory degree. After recovery of T₁ to 3%, cisatracurium was infused at an initial rate of 2 μg/(kg·min). The infusion rate was adjusted to maintain a constant 90% to 95% neuromuscular paralysis until the end of the operation. The onset time, no reaction period of TOF, the dosage of cisatracurium given during paleo-phepatic phase, an-hepatic phase and neo-hepatic phase, the time to 25% recovery of T₁, recovery index (25%?75%), and the time for the TOF ratio (TOFr) to reach 0.9 were recorded respectively.

Results·The infusion rate was (1.37±0.46) μg/(kg·min). The average infusion rate of drugs in the three different periods showed a downward trend, but there was no statistical difference (P=0.110). The onset time of cisatracurium was (242.63±46.74) s. The no reaction period of TOF was (34.02±7.71) min. Following termination of the infusion, the time to 25% recovery of T₁ was (12.80±3.49) min, and the recovery index (25%?75%) was (15.12±4.59) min. The time of TOFr=0.9 was (40.27±7.03) min.

Conclusion·The pharmacodynamical characteristics of muscle relaxants should be fully understood during living donor liver transplantation in infants and young children with end-liver disease. When cisatracurium (0.15 mg/kg) is used for anesthesia induction, endotracheal intubation should be performed 4 min after administration. In the maintenance stage of anesthesia, the infusion dose requirement of cisatracurium is basically unchanged in the three different periods,and the infusion rate of 1.4 μg/(kg·min) can provide satisfactory muscle relaxation effect.

Key words: liver transplantation, infants and young children, cisatracurium, pharmacodynamics

中图分类号:

R614.2

殷文, 王腾, 周雨曦, 杭燕南, 闻大翔. 婴幼儿活体肝移植术中静脉注射顺阿曲库铵的药效学研究[J]. 上海交通大学学报(医学版), 2021, 41(6): 761-763.

Wen YIN, Teng WANG, Yu-xi ZHOU, Yan-nan HANG, Da-xiang WEN. Pharmacodynamics of cisatracurium intravenously infused in infants and young children undergoing living donor liver transplantation[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 761-763.

图/表 1

参考文献 14

1	Rawal N, Yazigi N. Pediatric liver transplantation[J]. Pediatr Clin North Am, 2017, 64(3): 677-684.
2	Cammu G, Bossuyt G, De Baerdemaeker L, et al. Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation[J]. J Clin Anesth, 2002, 14(2):135-139.
3	De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation[J]. Br J Anaesth, 1996, 76(5): 624-628.
4	殷文, 闻大翔, 杭燕南. 婴幼儿活体肝移植术中罗库溴铵持续输注的药效学研究[J]. 上海交通大学学报(医学版), 2014, 34(9): 1381-1385.
5	ShangGuan W, Lian Q, Li J, et al. Clinical pharmacology of cisatracurium during nitrous oxide-propofol anesthesia in children[J]. J Clin Anesth, 2008, 20(6): 411-414.
6	Meakin GH, Meretoja OA, Perkins RJ, et al. Tracheal intubating conditions and pharmacodynamics following cisatracurium in infants and children undergoing halothane and thiopental-fentanyl anesthesia[J]. Paediatr Anaesth, 2007, 17(2):113-120.
7	温小林. 探讨不同剂量顺式阿曲库铵在小儿麻醉中对肌肉松弛的影响[J]. 中国医学前沿杂志(电子版), 2015, 7(1): 92-94.
8	周洁, 王祥瑞. 婴幼儿和成年患者活体肝移植术中顺阿曲库铵的药效学[J]. 中华麻醉学杂志, 2010(3): 262-265.
9	Guo J, Zhou X, Yuan X, et al. Age and the neuromuscular blockading effects of cisatracurium[J]. Int J Clin Exp Med, 2015, 8(9): 16664-16669.
10	Taivainen T, Meakin GH, Meretoja OA, et al. The safety and efficacy of cisatracurium 0.15 mg·kg^-1 during nitrous oxide-opioid anaesthesia in infants and children[J]. Anaesthesia, 2000, 55(11):1047-1051.
11	Xiaobo F, Jianjuan K, Yanlin W. Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia[J]. Braz J Med Biol Res, 2012, 45(7): 676-680.
12	朱宇麟, 景桂霞, 赵鸽, 等. 顺苯磺酸阿曲库铵在肝移植患者应用中的肌松效果及安全性[J]. 广东医学, 2009, 30(4): 588-589.
13	Withington D, Ménard G, Varin F. Cisatracurium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children[J]. Paediatr Anaesth, 2011, 21(3): 341-346.
14	Guo J, Yuan X, Zhou X, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients undergoing surgery with two hemodilution methods[J]. J Clin Anesth, 2017, 38: 75-80.

Index	Paleo-hepatic phase	An-hepatic phase	Neo-hepatic phase
Duration /min	195.2±50.77^①	45.38±7.80	168±47.94^①
Temperature /℃	36.6±0.69^②	35.96±0.79	36.71±0.89^③
Bleeding volume/mL	77.50±24.08^④	45.56±8.51	71.25±30.08^④
Blood pH	7.32±0.07	7.37±0.03^⑤	7.36±0.06^⑥
Blood transfusion volume /mL	40.00±47.06	59.38±41.71	87.50±71.88
Urine volume/mL·kg^-1·h^-1	5.21±4.41^⑦	5.96±4.35^⑦	12.24±4.82

Index	Paleo-hepatic phase	An-hepatic phase	Neo-hepatic phase
Duration /min	195.2±50.77^①	45.38±7.80	168±47.94^①
Temperature /℃	36.6±0.69^②	35.96±0.79	36.71±0.89^③
Bleeding volume/mL	77.50±24.08^④	45.56±8.51	71.25±30.08^④
Blood pH	7.32±0.07	7.37±0.03^⑤	7.36±0.06^⑥
Blood transfusion volume /mL	40.00±47.06	59.38±41.71	87.50±71.88
Urine volume/mL·kg^-1·h^-1	5.21±4.41^⑦	5.96±4.35^⑦	12.24±4.82

[1]	张天翼, 于也萍, 夏强, 杭化莲. 肝移植治疗慢加急性肝衰竭研究进展[J]. 上海交通大学学报(医学版), 2021, 41(2): 257-261.
[2]	李彭举，钟量，孙杰. 输尿管软镜联合钬激光碎石术治疗婴幼儿上尿路结石：单中心32例研究[J]. 上海交通大学学报（医学版）, 2020, 40(3): 408-.
[3]	姜燕，李红云，朱昌娥，傅月珍，魏嵘. 气管导管外放置封堵支气管插管与单腔气管导管在婴幼儿单肺通气中的应用比较[J]. 上海交通大学学报（医学版）, 2019, 39(5): 522-.
[4]	石惠卿,王红兵,陈津津 . 上海市静安区12月龄婴儿丹佛发育筛查及其智能发育相关因素分析#br#[J]. 上海交通大学学报（医学版）, 2017, 37(9): 1207-.
[5]	姜磊，王伟，沈佳，张蔚，唐嘉忠，朱德明. 改进型体外循环管道在婴幼儿体外循环中的应用[J]. 上海交通大学学报（医学版）, 2016, 36(04): 609-.
[6]	杨富，陈兰，方芳，等. 肝移植术后多重耐药菌感染危险因素的系统评价[J]. 上海交通大学学报（医学版）, 2015, 35(7): 1015-.
[7]	殷文，闻大翔，杭燕南. 婴幼儿活体肝移植术中罗库溴铵持续输注的药效学研究[J]. 上海交通大学学报（医学版）, 2014, 34(9): 1381-.
[8]	朱瑜洁, 赵培泉, 张琦. 129例永存原始玻璃体增生症的临床特征和术后疗效分析[J]. 上海交通大学学报（医学版）, 2013, 33(6): 846-.
[9]	沈燕, 张红. 肝移植受者术后生存体验的质性研究[J]. , 2013, 33(5): 556-.
[10]	李宏为, 彭承宏, 沈柏用, 等. 多模式部分肝移植关键技术及其临床应用[J]. , 2012, 32(9): 1198-.
[11]	钱道海, 沈柏用, 彭承宏, 等. 尸体供肝移植术后被动肝动脉缓冲效应的相关研究[J]. , 2012, 32(6): 771-.
[12]	孙瑛, 朱明, 张剑蔚, 等. 七氟醚预处理和后处理对婴幼儿体外循环心肌再灌注损伤的影响[J]. , 2011, 31(9): 1316-.
[13]	陆晔峰, 赵爱平, 王艳. 肝移植护理伦理问题的研究进展[J]. , 2011, 31(6): 723-.
[14]	朱亚菊, 林芊, 华丽, 等. 布地奈德混悬液联合妥洛特罗贴剂治疗婴幼儿反复喘息的疗效及安全性研究[J]. , 2011, 31(12): 1729-.
[15]	王丽亚, 董彦清, 张鹏举, 等. 脱细胞异体真皮基质生物补片修补新生儿及婴幼儿组织缺损[J]. , 2011, 31(1): 115-.